Search results for "Steatosi"
showing 10 items of 261 documents
Emerging Increase in the prevalence and severity of nonalcoholic fatty liver disease: epidemiological study from general Mediterranean population
2016
Background and Aims: The worldwide spread of obesity and diabetes is leading to a drastic increase in nonalcoholic fatty liver disease (NAFLD) and its complications.We aimed to assess prevalence of NAFLD and of its severity among a general Mediterranean population. Methods:We considered 886 consecutive individuals included in the ABCD study (ISRCTN15840340). Hepatic ultrasound (US) was used to diagnose steatosis and FibroScan (M and XL probe) to measure liver stiffness and controlled attenuation parameter (CAP). Liver stiffness >6.9 KPa was considered suggestive of significant liver fibrosis (Petta S et al., Hepatology 2015), and CAP ≥ 310 dB was considered suggestive of moderate-severe …
Chronic hepatitis C infection and insulin resistance: two best friends.
2011
Approximately 170 million people worldwide are chronically infected by HCV, which can result in progressive hepatic injury and fibrosis, culminating in cirrhosis and end-stage liver disease. Among ...
Mitochondrial involvement in non-alcoholic steatohepatitis
2007
Non-alcoholic steatohepatitis (NASH) is an increasing recognized condition that may progress to end-stage liver disease. There are consistent evidences that mitochondrial dysfunction plays a central role in NASH whatever its origin. Mitochondria are the key controller of fatty acids removal and this is part of an intensive gene program that modifies hepatocytes to counteract the excessive fat storage. Mitochondrial dysfunction participates at different levels in NASH pathogenesis since it impairs fatty liver homeostasis and induces overproduction of ROS that in turn trigger lipid peroxidation, cytokines release and cell death. In this review we briefly recall the role of mitochondria in fat…
Science to Practice: Should Biopsy Be Performed in Potential Liver Donors When Unenhanced CT Shows an Unacceptable Degree of Steatosis for Transplant…
2006
Park et al (1) have demonstrated that unenhanced CT can accurately depict moderate to severe (ie, ≥30%) macrovesicular steatosis, thereby allowing avoidance of biopsy in potential living liver donors who have an unacceptable degree of steatosis for transplantation. Biopsy will still be needed in donors with macrovesicular steatosis of less than 30% at unenhanced CT to rule out occult chronic liver disease and more severe steatosis that is undetected at CT. © RSNA, 2006.
Reply to: “Is industrial fructose just a marker of an unhealthy dietary pattern?”
2014
We recently reported a link between fructose intake and the severity of liver fibrosis in a cohort of Italian patients with genotype 1 (G1) chronic hepatitis C (CHC) [1]. In particular, the association holds true for ‘‘industrial’’ only, not for ‘‘fruit’’ fructose intake. We thank Chiavaroli and colleagues for their comments that give us the opportunity to further strengthen data from our analyses.
Therapeutic effect of fractionated by ultrafiltration red beetroot (Beta vulgaris l.) juice in rats with food-induced fatty liver
2019
The prevalence of non-alcoholic fatty liver disease (NAFLD), being a component of metabolic syndrome, has increased (15-27%) in the industrialized world. The deep mechanism of this pathology is not clear, but it is multifactorial. There is a huge amount of food supplements and medicines with hepatoprotective effect on the market, but the NAFLD problem is far from being resolved. Hepatoprotective products have to provide wide spectra of biological effects, including antioxidant, hypolipidemic, anti-inflammatory action. It is peculiar to natural compounds, including red beetroot juice, which is well known to most of the population. This is important in view of the high prevalence of NAFLD. Th…
Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: From a Clinical to a Molecular Association
2009
Hepatocellular carcinoma (HCC) is the most frequent primary neoplasm of the liver, and is the fourth most common malignancy worldwide. It is also the third leading cause of cancer-related deaths. Most cases of HCC develop on a pre-existing chronic liver disease, usually due to hepatitis C virus (HCV), hepatitis B virus (HBV), or alcohol. However, between 15% and 50% of HCC develops in the absence of a known etiology of liver disease, and different lines of evidence identify in non-alcoholic fatty liver disease (NAFLD) a possible relevant risk factor for occurrence of HCC. Insulin resistance (IR), steatosis, oxidative stress and imbalances in adipokine/cytokine interplay, the most important …
Animal models of non-alcoholic steatohepatitis: of mice and man.
2010
The epidemic occurrence of obesity has led to a rapid increase in the incidence of non-alcoholic fatty liver disease (NAFLD) in industrial countries. The disease spectrum includes hepatic steatosis, lobular inflammation with steatohepatitis (NASH) and varying degrees of liver fibrosis, which can progress to cirrhosis. Hepatocellular carcinoma can develop in patients with NASH, even in the absence of cirrhosis. The majority of patients with primary NASH exhibit risk factors that define the metabolic syndrome including insulin resistance and visceral obesity. However, only a minority of patients with NAFLD progress to end-stage liver disease and, so far, predictors to identify these patients …
Die Milz bei Lebererkrankungen
1970
In patients with diseases of the liver portal hypertension and cellular proliferation produce reactive changes in the spleen. The size of the spleen and its function as a filter were determined quantitatively with isotope-labeled, heat-induced spherocytes. In 96% of the investigated liver diseases (acute and chronic hepatitis, cirrhosis and steatosis of the liver) either the size or the filter function of the organ are altered, frequently both of them.